Published in Cardiol Rev on February 06, 2015
How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood (2016) 0.75
Massive adrenal vein aneurysm mimicking an adrenal tumor in a patient with hemophilia A: a case report and review of the literature. J Med Case Rep (2016) 0.75
Perioperative management and monitoring of antiplatelet agents: a focused review on aspirin and P2Y12 inhibitors. Korean J Anesthesiol (2017) 0.75
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med (2007) 6.76
Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg (2003) 2.71
Haemophilias A and B. Lancet (2003) 2.68
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood (2007) 2.67
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol (2008) 2.46
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost (2004) 2.20
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost (2006) 2.01
Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. JACC Cardiovasc Interv (2012) 1.74
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Abciximab for the treatment of an acute thrombotic coronary occlusion during stent implantation in a patient with severe hemophilia B. Ital Heart J (2003) 1.70
Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg (2008) 1.68
Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc (2010) 1.58
Cardiovascular risk assessment in haemophilia patients. Thromb Haemost (2010) 1.57
Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet (1999) 1.47
Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia (2011) 1.47
How we treat a hemophilia A patient with a factor VIII inhibitor. Blood (2008) 1.24
Perioperative use of the Thrombelastograph in patients with inherited bleeding disorders. J Clin Anesth (2003) 1.13
Coronary artery calcification score and carotid intima–media thickness in patients with hemophilia. J Thromb Haemost (2012) 1.12
The case for wider use of recombinant factor VIII concentrates. Crit Rev Oncol Hematol (2011) 1.11
Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost (2012) 1.11
Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol (2005) 1.01
Open-heart surgery in patients with hematologic disorders. Am Heart J (1983) 1.01
Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost (2012) 0.95
Cardiac surgery and catheterization in patients with haemophilia. Haemophilia (2000) 0.95
Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol (1992) 0.95
Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia (2002) 0.94
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia (2007) 0.94
Emerging clinical concerns in the ageing haemophilia patient. Haemophilia (2009) 0.93
Successful multi-vessel percutaneous coronary intervention with bivalirudin in a patient with severe hemophilia A: a case report and review of literature. J Invasive Cardiol (2004) 0.93
Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med (1995) 0.92
How I treat age-related morbidities in elderly persons with hemophilia. Blood (2009) 0.92
The modern treatment of haemophilia: a narrative review. Blood Transfus (2012) 0.91
Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol (2006) 0.90
Percutaneous coronary intervention with stent implantation in haemophilic A patient with unstable angina. Haemophilia (2007) 0.90
Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost (2012) 0.89
Hemostatic management of an infant with severe hemophilia A and tetralogy of Fallot for cardiac bypass surgery. Pediatr Blood Cancer (2010) 0.89
Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. Ann Thorac Surg (2008) 0.89
Pharmacologic interventions for reversing the effects of oral anticoagulants. Am J Health Syst Pharm (2013) 0.89
Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation (2001) 0.88
Clinical perspectives of emerging pathogens in bleeding disorders. Lancet (2006) 0.88
Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis (2011) 0.88
Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia (2012) 0.87
Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost (2009) 0.86
Treatment of a patient with factor IX deficiency (hemophilia B) with coronary bypass surgery. J Thorac Cardiovasc Surg (1993) 0.86
Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia (2010) 0.86
Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia (2001) 0.85
Anticoagulation in haemophilia patients with prosthetic valve replacement. Haemophilia (2004) 0.84
The effect of desmopressin on reducing blood loss in cardiac surgery--a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost (1995) 0.84
Pediatric hemophilia: a review. Semin Thromb Hemost (2011) 0.84
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia (2009) 0.83
Desmopressin and antifibrinolytics. Int Anesthesiol Clin (1990) 0.82
Do patients with haemophilia undergoing cardiac surgery have good surgical outcomes? Interact Cardiovasc Thorac Surg (2011) 0.82
Aortic valve replacement in a patient with severe hemophilia. Coll Antropol (2007) 0.82
Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb Res (1981) 0.82
Successful percutaneous coronary intervention in a patient with severe haemophilia A using bivalirudin as the sole procedural anticoagulant. Haemophilia (2005) 0.82
Increased prevalence of hypertension in haemophilia patients. Thromb Haemost (2012) 0.81
A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery. Int J Cardiol (2009) 0.81
Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost (2001) 0.81
Management of an acute coronary syndrome in a patient with severe haemophilia A. Haemophilia (2007) 0.81
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med (2012) 0.80
Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia (2009) 0.79
Treatment for abdominal aortic aneurysm in a patient with hemophilia A: a case report and review of the literature. J Vasc Surg (1997) 0.79
The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost (2010) 0.79
Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 0.79
Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: a single center experience and review of the literature. Thromb Res (2012) 0.79
Percutaneous coronary intervention in a patient with acute non-ST-elevation myocardial infarction and haemophilia A: a 'genous' experience. Haemophilia (2011) 0.78
Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A. Haemophilia (2011) 0.78
Acute type-a dissection in a patient with severe hemophilia A. J Cardiothorac Vasc Anesth (2011) 0.78
Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose of desmopressin. Thromb Haemost (2004) 0.78
Percutaneous coronary intervention in a patient with acute ST-elevation myocardial infarction and hemophilia A. J Invasive Cardiol (2008) 0.78
Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group. Haemophilia (2013) 0.77
Hemophilia and percutaneous coronary interventions. Ital Heart J (2003) 0.77
Aging in haemophilia: getting to the heart of the matter. Thromb Haemost (2011) 0.77
Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A. Eur J Anaesthesiol (2004) 0.77
The use of desmopressin in open-heart surgery. Haemophilia (2008) 0.77
Adenotonsillectomy in patients with desmopressin responsive mild bleeding disorders: a review of the literature. Haemophilia (2009) 0.76
Aortic and mitral valve replacement in a patient with hemophilia B. Asian Cardiovasc Thorac Ann (2007) 0.76
Heart surgery in infants with hemophilia. Ann Thorac Surg (2006) 0.76
Cardiac surgery in patients with haemophilia B: a case report and review of the literature. Haemophilia (2008) 0.76
Cardiac surgery in patients with haemophilia. Haemophilia (2009) 0.76
Endovascular abdominal aortic aneurysm repair in a patient with severe hemophilia B. J Endovasc Ther (2009) 0.76
Modified Bentall operation in a patient with hemophilia A. Jpn J Thorac Cardiovasc Surg (2003) 0.76
Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment. Thromb Haemost (2010) 0.76
Transcatheter closure of patent ductus arteriosus in a patient with haemophilia-A. Indian Heart J (2000) 0.76
Use of factor VIII replacement during open heart surgery in a patient with haemophilia A. Haemophilia (2006) 0.76
Acute left anterior descending artery occlusion in a hemophiliac A patient during recombinant factor VIII infusion: treatment with coronary angioplasty. Catheter Cardiovasc Interv (2000) 0.76
Hemophilia A in cardiac operations: a model of reduced thrombin generation. Ann Thorac Surg (2011) 0.76
Impact of lifestyle modification on symptomatic coronary artery disease in a haemophilia patient with inhibitors. Haemophilia (2011) 0.76
Dilated cardiomyopathy in haemophiliacs infected with the human immunodeficiency virus. Scott Med J (1993) 0.76
Successful double bypass in a patient with severe hemophilia A: a case report. J Thromb Thrombolysis (2012) 0.76
Perioperative management of coronary artery bypass surgery in a patient with factor IX deficiency. J Cardiothorac Vasc Anesth (1991) 0.76
A severe haemophiliac patient with acute coronary syndrome admitted to cardiac rehabilitation. Haemophilia (2012) 0.76
Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med (1988) 0.76
Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest (2005) 2.46
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27
Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet (2003) 1.82
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood (2003) 1.60
Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. J Biol Chem (2002) 1.59
Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2002) 1.57
Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.52
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica (2005) 1.51
Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 1.47
Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood (2007) 1.45
The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood (2004) 1.33
Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis (2009) 1.33
Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets (2008) 1.27
How we treat a hemophilia A patient with a factor VIII inhibitor. Blood (2008) 1.24
Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol (2009) 1.23
Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21
Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res (2008) 1.20
Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res (2007) 1.19
Src family kinases mediate neutrophil adhesion to adherent platelets. Blood (2006) 1.16
Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med (2013) 1.15
A critical role of Rap1b in B-cell trafficking and marginal zone B-cell development. Blood (2008) 1.12
Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem (2011) 1.11
Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res (2013) 1.11
Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions. Clin Sci (Lond) (2011) 1.10
Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res (2013) 1.09
Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability. Arterioscler Thromb Vasc Biol (2014) 1.08
A phosphatidic acid binding/nuclear localization motif determines lipin1 function in lipid metabolism and adipogenesis. Mol Biol Cell (2010) 1.07
Src-family kinases mediate an outside-in signal necessary for beta2 integrins to achieve full activation and sustain firm adhesion of polymorphonuclear leucocytes tethered on E-selectin. Biochem J (2006) 1.05
Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun (2013) 1.05
Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler Thromb Vasc Biol (2012) 1.04
CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol (2006) 1.04
Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res (2010) 1.04
Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res (2013) 1.03
Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol (2009) 1.03
Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol (2008) 1.02
Rap1b regulates B cell development, homing, and T cell-dependent humoral immunity. J Immunol (2008) 1.01
Distinct roles for Rap1b protein in platelet secretion and integrin αIIbβ3 outside-in signaling. J Biol Chem (2011) 1.01
Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood (2005) 1.00
Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol (2009) 0.99
Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes. J Exp Med (2010) 0.97
Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology (2002) 0.97
Evidence of mobilization of pluripotent stem cells into peripheral blood of patients with myocardial ischemia. Exp Hematol (2010) 0.92
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J (2011) 0.91
Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol (2010) 0.91
Functional characterization of the atypical integral membrane lipid phosphatase PDP1/PPAPDC2 identifies a pathway for interconversion of isoprenols and isoprenoid phosphates in mammalian cells. J Biol Chem (2010) 0.90
Integrin-independent role of CalDAG-GEFI in neutrophil chemotaxis. J Leukoc Biol (2010) 0.90
Measurement of autotaxin/lysophospholipase D activity. Methods Enzymol (2007) 0.90
Platelet secretion and hemostasis require syntaxin-binding protein STXBP5. J Clin Invest (2014) 0.89
Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev (2013) 0.87
A reference system approach to future standardization of laboratory tests for hemostasis. A position paper of the Joint Committee of the IFCC Scientific Division and the ISTH Scientific and Standardization Committee. Thromb Haemost (2002) 0.87
Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. Arterioscler Thromb Vasc Biol (2011) 0.87
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86
CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury. PLoS One (2011) 0.85
Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis (2013) 0.84
Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation. Trends Cardiovasc Med (2009) 0.84
Parent-of-origin effects on cardiac response to pressure overload in mice. Am J Physiol Heart Circ Physiol (2009) 0.84
B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood (2013) 0.84
Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol (2007) 0.84
Synergistic effect of anemia and red blood cells transfusion on inflammation and lung injury. Adv Hematol (2012) 0.83
Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J (2013) 0.83
Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS One (2012) 0.83
Lysophosphatidic acid and cardiovascular disease: seeing is believing. J Lipid Res (2013) 0.82
Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol (2012) 0.81
Lysophospholipids in coronary artery and chronic ischemic heart disease. Curr Opin Lipidol (2015) 0.81
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost (2014) 0.80
Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study. J Thromb Thrombolysis (2012) 0.79
Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol (2013) 0.79
Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis (2011) 0.79
Hemophilia gene therapy: update. Curr Opin Hematol (2002) 0.79
Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. Circ Cardiovasc Interv (2012) 0.78
The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. PLoS One (2012) 0.78
Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism. Thromb Res (2010) 0.78
Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol (2010) 0.78
Renal lymphoma: unusual lymphoproliferative manifestation of Sjogren's syndrome. J Rheumatol (2013) 0.78
Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. J Thromb Thrombolysis (2014) 0.78
Pathophysiology and pharmacologic treatment of venous thromboembolism. Curr Drug Targets (2014) 0.77
Preventing platelet thrombosis with a PAR1 pepducin. Circulation (2012) 0.77
Novel mediators and biomarkers of thrombosis. J Thromb Thrombolysis (2014) 0.77
The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis (2015) 0.77
The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome. J Am Coll Cardiol (2015) 0.77
In-stent restenosis: more fuel for the fire. Am Heart J (2002) 0.76
Tissue necrosis factor α and targeting its receptor in ischaemic heart disease. Heart (2013) 0.76
Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J (2010) 0.75
Connexin 37 counteracts clotting. Circulation (2011) 0.75
Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care? South Med J (2013) 0.75
Invasive coronary vasoreactivity testing to diagnose microvascular dysfunction in women. JACC Cardiovasc Interv (2012) 0.75
Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions. Curr Cardiol Rev (2016) 0.75
Mutations in and near the second calcium-binding domain of integrin alphaIIb affect the structure and function of integrin alphaIIbbeta3. Biochem J (2004) 0.75
Management of pregnancy in a patient with severe hemophilia type a. AJP Rep (2012) 0.75
Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel) (2013) 0.75
Platelet function analysis: at the edge of meaning. Thromb Haemost (2009) 0.75
The case against routine aspirin use for primary prevention in low-risk adults. Am Fam Physician (2011) 0.75
G-protein binding features and regulation of the RalGDS family member, RGL2. Biochem J (2008) 0.75
A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance. Clin Cardiol (2007) 0.75